CellMed 2024; 14(5): 5.1-5.4
Published online April 30, 2024
https://doi.org/10.5667/CellMed.spc.079
© Cellmed Orthocellular Medicine and Pharmaceutical Association
최연 약사
광주 서구 운천로 88 운진빌딩 한샘약국
Correspondence to : Yeon choi
E-mail: cy386@hanmail.net
☨ This report has been translated and edited by the CellMed editor-in-chief, Prof. Beom-Jin Lee.
This is an open access article under the CC BY-NC license. (http://creativecommons.org/licenses/by-nc/3.0/)
Objective: To report a case of postoperative improvement in a uterine cancer patient using Ortho-Cellular Nutrition Therapy (OCNT).
Methods: A Korean woman in her fifties suffering from postoperative complications associated with uterine cancer treatment.
Results: Significant improvement in various indicators was noted following the administration of nutritional therapy after uterine cancer surgery.
Conclusion: OCNT may aid in alleviating symptoms following uterine cancer surgery.
Keywords Ortho-Cellular Nutrition Therapy (OCNT), uterine cancer, cancer surgery, postoperative complications
Gynecological cancers, ranging from ovarian to vulvar, represent malignant tumors that develop along the female reproductive tract. These cancers account for 15.2% of all global female cancer cases and deaths. According to the 2020 GLOBOCAN report, there are 417,367 new cases and 97,370 deaths from uterine cancer worldwide annually.1
Uterine cancer is categorized into endometrial cancer and non-endometrial cancers, such as uterine sarcomas. In Korea, the incidence of uterine cancer increased 3.6-fold from 949 cases in 1999 to 3,437 in 2019. The age-standardized incidence rate of uterine cancer saw an average annual percentage change of 4.7 from 1999 to 2019. The three-year, five-year, and ten-year survival rates for uterine cancer are 89.0% (95% confidence interval, 88.6% to 89.3%), 86.3% (95% confidence interval, 85.8% to 86.7%), and 83.3% (95% confidence interval, 82.8% to 83.8%) respectively.2
Obesity is a significant risk factor for endometrial cancer, with other factors including diabetes, hypertension, and polycystic ovary syndrome. Factors such as childbirth, contraceptive use, and menopausal hormone therapy also influence risk.3
The most common types of uterine sarcomas are leiomyosarcoma (LMS, 63%), endometrial stromal sarcoma (ESS, 21%), adenosarcoma (6%), undifferentiated sarcoma (5%), and others (5%). Little is known about the causes of uterine sarcoma.4
Treatment options for uterine cancer include hysterectomy, radiation therapy, chemotherapy, targeted therapy, and hormone therapy.
This report follows a uterine cancer patient who experienced a noticeable improvement in postoperative recovery and symptom reduction following nutritional therapy, consented by the patient for case reporting.
A single case of a uterine cancer patient.
1) Name: Park OO (F/56 years old)
2) Diagnosis: Stage II uterine cancer
3) Date of diagnosis: February 2023, diagnosed with Stage II uterine cancer (4cm) at Seoul OO Hospital
4) Treatment duration: From March 7, 2023, to present
5) Main symptoms: Hematuria, loss of appetite, anxiety about surgery and cancer treatment, lethargy
6) Past medical history: Uterine bleeding in July 2022, atrophic gastritis, colon polyps, menopause in December 2021
7) Social history: None
8) Family history: Gastric cancer, cardiac arrest
9) Current illness and medications: Symbicort
1st OCNT (15-day course):
Paragon (101, twice a day, one sachet per intake) for five days
Bioplex (101, twice a day, one sachet per intake) for five days
Cyaplex F (222, three times a day, two sachets per intake)
Eufaplex (111, three times a day, one capsule per intake)
Betaplex (111, three times a day, one sachet per intake)
Enzaplex (111, three times a day, one sachet per intake)
Nutaplex (111, three times a day, one sachet per intake)
Selenplex (222, three times a day, two capsules per intake)
Aqua SAC (10 10 10, three times a day, 10 mL per intake)
2nd OCNT phases (2nd to 5th):
Cyaplex F (202, twice a day, two sachets per intake)
Eufaplex (101, twice a day, one capsule per intake)
Betaplex (101, twice a day, one sachet per intake)
Bioplex (101, twice a day, one sachet per intake)
Selenplex (202, twice a day, two capsules per intake)
Diverol (020, once a day, two capsules per intake)
Aqua SAC (10 0 10, twice a day, 10mL per intake)
6th OCNT phase (September 2023 to January 2024):
Cyaplex F (101, twice a day, one sachet per intake)
Resplex (101, twice a day, one sachet per intake)
Eufaplex (101, twice a day, one capsule per intake)
Diverol (010, once a day, one capsule per intake)
Selenplex (101, twice a day, one capsule per intake)
Bioplex (001, once a day, one sachet per intake)
7th OCNT phase (Starting February 2024):
Continuing the 6th phase regimen with additions:
Enzaplex (101, twice a day, one sachet per intake)
Tmplex: (101, twice a day, one capsule per intake)
The patient was diagnosed with Stage II uterine cancer with a 4cm tumor in February 2023 at Seoul OO Hospital and was scheduled for chemotherapy and radiation therapy after surgery.
OCNT was initiated pre-surgery to aid in rapid recovery and reduce postoperative complications.
After a single dose of the initial OCNT, the patient experienced significant gas release. After surgery on March 21, the patient was hospitalized for three days and was discharged in good health. The biopsy of the excised tissue indicated that no further chemotherapy or radiation was necessary, and quarterly CT scans were recommended.
Following OCNT from the 2nd to the 5th phase, a routine check-up in July 2023 showed no abnormalities, and the regular check-up interval was extended to six months starting October 2023. In February 2024, examination results showed that white blood cell counts that were abnormally high before surgery, had normalized (Fig. 1). Also, red blood cell counts and hemoglobin levels, which were bellowed the baseline, were restored to normal (Figs. 2 and 3). The tumor marker CA-125 levels were also within reference ranges at 3.3, 4.3, and 4.1 in three subsequent blood tests after surgery.
These results demonstrate that consistent OCNT, initiated before and continued after surgery, has significantly improved the patient’s physical and mental quality of life.
The subject of this case study is a Korean woman in her fifties who began experiencing uterine bleeding in July 2022. At that time, no uterine cancer was detected, but in February 2023, a 4cm tumor was identified at Samsung OO Hospital, leading to a diagnosis of Stage II uterine cancer.
The subject initially experienced dyspeptic symptoms, and a five-day regimen of Paragon and Bioplex was started. Ingredients in Paragon, such as fennel5, buckwheat6, and clove7, aid in alleviating indigestion. Additionally, the oat fiber in Bioplex improves gut microbiota and is beneficial for cancer8,9, and its fructooligosaccharides enhance mineral absorption and promote intestinal fermentation10.
Cyaplex F's anthocyanins modulate anti-inflammatory responses, inhibit mutagenesis, induce differentiation, regulate signaling pathways, and arrest the cell cycle. They also stimulate apoptosis or autophagy in cancer cells, thereby suppressing proliferation, preventing invasion, reversing drug resistance, and enhancing sensitivity to chemotherapy11. It has also been shown to induce cell cycle progression and apoptosis in uterine and colorectal cancers12.
Eufaplex's oleic acid is beneficial for autoimmune and inflammatory diseases and has been effective against cancer13. Linolenic acid is shown to inhibit cancer cell growth and induce apoptosis effectively14.
Betaplex's beta-glucans have been shown to significantly reduce the viability of cancer cells with increasing concentrations and incubation time15.
Enzaplex, containing a blend of protease, amylase, lipase, bromelain, gingerol, rutin, fucoidan, laminarin, and dietary fibers, not only aids digestion16-24 but also has anti-cancer benefits. Bromelain also induces apoptosis, reduces cancer cells through autophagy, regulates immunity, and reduces inflammatory edema associated with surgery25.
Nutaplex’s chlorophyll and spirulina powder possess outstanding antioxidant capabilities26,27, with chlorophyll having anti-mutagenic and anti-genotoxic properties and anti-cancer effects28. Spirulina also exhibits anti-cancer and antiviral capabilities29.
Selenplex’s selenium functions in antioxidation, anti-inflammation, reducing cancer incidence, blocking tumor invasion and metastasis, and boosting immunity, thereby naturally preventing cancer recurrence and aiding in pre- and post-surgery management30.
Low vitamin D levels and inadequate calcium intake are risk factors for various cancers31, hence we added a Diverol and Aqua SAC. Aqua SAC's calcium facilitates the regulation of calcium signaling, which plays a dual role in the survival and death of cancer cells32. Diverol’s vitamin D supports the absorption of this calcium33.
Resplex’s resveratrol inhibits the conversion of procarcinogens to carcinogens, thereby suppressing cancer and preventing cancer in various ways34.
Finally, Tmplex's micronutrients are essential for immune system function and inflammation control, and they are added to reduce immune and inflammatory responses before and after surgery for uterine cancer35.
This case report represents a single instance and is not universally applicable to all postoperative uterine cancer patients. However, with the patient’s consent, it is reported that there was significant improvement after implementing OCNT.
CellMed 2024; 14(5): 5.1-5.4
Published online April 30, 2024 https://doi.org/10.5667/CellMed.spc.079
Copyright © Cellmed Orthocellular Medicine and Pharmaceutical Association.
최연 약사
광주 서구 운천로 88 운진빌딩 한샘약국
Pharmacist, Yeon Choi
Hansaem Pharmacy, 88, Unjin Building, Uncheon-ro, Seo-gu, Gwangju, Republic of Korea
Correspondence to:Yeon choi
E-mail: cy386@hanmail.net
☨ This report has been translated and edited by the CellMed editor-in-chief, Prof. Beom-Jin Lee.
This is an open access article under the CC BY-NC license. (http://creativecommons.org/licenses/by-nc/3.0/)
Objective: To report a case of postoperative improvement in a uterine cancer patient using Ortho-Cellular Nutrition Therapy (OCNT).
Methods: A Korean woman in her fifties suffering from postoperative complications associated with uterine cancer treatment.
Results: Significant improvement in various indicators was noted following the administration of nutritional therapy after uterine cancer surgery.
Conclusion: OCNT may aid in alleviating symptoms following uterine cancer surgery.
Keywords: Ortho-Cellular Nutrition Therapy (OCNT), uterine cancer, cancer surgery, postoperative complications
Gynecological cancers, ranging from ovarian to vulvar, represent malignant tumors that develop along the female reproductive tract. These cancers account for 15.2% of all global female cancer cases and deaths. According to the 2020 GLOBOCAN report, there are 417,367 new cases and 97,370 deaths from uterine cancer worldwide annually.1
Uterine cancer is categorized into endometrial cancer and non-endometrial cancers, such as uterine sarcomas. In Korea, the incidence of uterine cancer increased 3.6-fold from 949 cases in 1999 to 3,437 in 2019. The age-standardized incidence rate of uterine cancer saw an average annual percentage change of 4.7 from 1999 to 2019. The three-year, five-year, and ten-year survival rates for uterine cancer are 89.0% (95% confidence interval, 88.6% to 89.3%), 86.3% (95% confidence interval, 85.8% to 86.7%), and 83.3% (95% confidence interval, 82.8% to 83.8%) respectively.2
Obesity is a significant risk factor for endometrial cancer, with other factors including diabetes, hypertension, and polycystic ovary syndrome. Factors such as childbirth, contraceptive use, and menopausal hormone therapy also influence risk.3
The most common types of uterine sarcomas are leiomyosarcoma (LMS, 63%), endometrial stromal sarcoma (ESS, 21%), adenosarcoma (6%), undifferentiated sarcoma (5%), and others (5%). Little is known about the causes of uterine sarcoma.4
Treatment options for uterine cancer include hysterectomy, radiation therapy, chemotherapy, targeted therapy, and hormone therapy.
This report follows a uterine cancer patient who experienced a noticeable improvement in postoperative recovery and symptom reduction following nutritional therapy, consented by the patient for case reporting.
A single case of a uterine cancer patient.
1) Name: Park OO (F/56 years old)
2) Diagnosis: Stage II uterine cancer
3) Date of diagnosis: February 2023, diagnosed with Stage II uterine cancer (4cm) at Seoul OO Hospital
4) Treatment duration: From March 7, 2023, to present
5) Main symptoms: Hematuria, loss of appetite, anxiety about surgery and cancer treatment, lethargy
6) Past medical history: Uterine bleeding in July 2022, atrophic gastritis, colon polyps, menopause in December 2021
7) Social history: None
8) Family history: Gastric cancer, cardiac arrest
9) Current illness and medications: Symbicort
1st OCNT (15-day course):
Paragon (101, twice a day, one sachet per intake) for five days
Bioplex (101, twice a day, one sachet per intake) for five days
Cyaplex F (222, three times a day, two sachets per intake)
Eufaplex (111, three times a day, one capsule per intake)
Betaplex (111, three times a day, one sachet per intake)
Enzaplex (111, three times a day, one sachet per intake)
Nutaplex (111, three times a day, one sachet per intake)
Selenplex (222, three times a day, two capsules per intake)
Aqua SAC (10 10 10, three times a day, 10 mL per intake)
2nd OCNT phases (2nd to 5th):
Cyaplex F (202, twice a day, two sachets per intake)
Eufaplex (101, twice a day, one capsule per intake)
Betaplex (101, twice a day, one sachet per intake)
Bioplex (101, twice a day, one sachet per intake)
Selenplex (202, twice a day, two capsules per intake)
Diverol (020, once a day, two capsules per intake)
Aqua SAC (10 0 10, twice a day, 10mL per intake)
6th OCNT phase (September 2023 to January 2024):
Cyaplex F (101, twice a day, one sachet per intake)
Resplex (101, twice a day, one sachet per intake)
Eufaplex (101, twice a day, one capsule per intake)
Diverol (010, once a day, one capsule per intake)
Selenplex (101, twice a day, one capsule per intake)
Bioplex (001, once a day, one sachet per intake)
7th OCNT phase (Starting February 2024):
Continuing the 6th phase regimen with additions:
Enzaplex (101, twice a day, one sachet per intake)
Tmplex: (101, twice a day, one capsule per intake)
The patient was diagnosed with Stage II uterine cancer with a 4cm tumor in February 2023 at Seoul OO Hospital and was scheduled for chemotherapy and radiation therapy after surgery.
OCNT was initiated pre-surgery to aid in rapid recovery and reduce postoperative complications.
After a single dose of the initial OCNT, the patient experienced significant gas release. After surgery on March 21, the patient was hospitalized for three days and was discharged in good health. The biopsy of the excised tissue indicated that no further chemotherapy or radiation was necessary, and quarterly CT scans were recommended.
Following OCNT from the 2nd to the 5th phase, a routine check-up in July 2023 showed no abnormalities, and the regular check-up interval was extended to six months starting October 2023. In February 2024, examination results showed that white blood cell counts that were abnormally high before surgery, had normalized (Fig. 1). Also, red blood cell counts and hemoglobin levels, which were bellowed the baseline, were restored to normal (Figs. 2 and 3). The tumor marker CA-125 levels were also within reference ranges at 3.3, 4.3, and 4.1 in three subsequent blood tests after surgery.
These results demonstrate that consistent OCNT, initiated before and continued after surgery, has significantly improved the patient’s physical and mental quality of life.
The subject of this case study is a Korean woman in her fifties who began experiencing uterine bleeding in July 2022. At that time, no uterine cancer was detected, but in February 2023, a 4cm tumor was identified at Samsung OO Hospital, leading to a diagnosis of Stage II uterine cancer.
The subject initially experienced dyspeptic symptoms, and a five-day regimen of Paragon and Bioplex was started. Ingredients in Paragon, such as fennel5, buckwheat6, and clove7, aid in alleviating indigestion. Additionally, the oat fiber in Bioplex improves gut microbiota and is beneficial for cancer8,9, and its fructooligosaccharides enhance mineral absorption and promote intestinal fermentation10.
Cyaplex F's anthocyanins modulate anti-inflammatory responses, inhibit mutagenesis, induce differentiation, regulate signaling pathways, and arrest the cell cycle. They also stimulate apoptosis or autophagy in cancer cells, thereby suppressing proliferation, preventing invasion, reversing drug resistance, and enhancing sensitivity to chemotherapy11. It has also been shown to induce cell cycle progression and apoptosis in uterine and colorectal cancers12.
Eufaplex's oleic acid is beneficial for autoimmune and inflammatory diseases and has been effective against cancer13. Linolenic acid is shown to inhibit cancer cell growth and induce apoptosis effectively14.
Betaplex's beta-glucans have been shown to significantly reduce the viability of cancer cells with increasing concentrations and incubation time15.
Enzaplex, containing a blend of protease, amylase, lipase, bromelain, gingerol, rutin, fucoidan, laminarin, and dietary fibers, not only aids digestion16-24 but also has anti-cancer benefits. Bromelain also induces apoptosis, reduces cancer cells through autophagy, regulates immunity, and reduces inflammatory edema associated with surgery25.
Nutaplex’s chlorophyll and spirulina powder possess outstanding antioxidant capabilities26,27, with chlorophyll having anti-mutagenic and anti-genotoxic properties and anti-cancer effects28. Spirulina also exhibits anti-cancer and antiviral capabilities29.
Selenplex’s selenium functions in antioxidation, anti-inflammation, reducing cancer incidence, blocking tumor invasion and metastasis, and boosting immunity, thereby naturally preventing cancer recurrence and aiding in pre- and post-surgery management30.
Low vitamin D levels and inadequate calcium intake are risk factors for various cancers31, hence we added a Diverol and Aqua SAC. Aqua SAC's calcium facilitates the regulation of calcium signaling, which plays a dual role in the survival and death of cancer cells32. Diverol’s vitamin D supports the absorption of this calcium33.
Resplex’s resveratrol inhibits the conversion of procarcinogens to carcinogens, thereby suppressing cancer and preventing cancer in various ways34.
Finally, Tmplex's micronutrients are essential for immune system function and inflammation control, and they are added to reduce immune and inflammatory responses before and after surgery for uterine cancer35.
This case report represents a single instance and is not universally applicable to all postoperative uterine cancer patients. However, with the patient’s consent, it is reported that there was significant improvement after implementing OCNT.
Pharmacist, Mijin Kim
CellMed 2025; 15(1): 4.1-4.3Pharmacist, Jeonga Park
CellMed 2025; 15(1): 3.1-3.3Pharmacist, Jong-Bin Jo
CellMed 2025; 15(1): 2.1-2.3